Published on

Urology – Metastatic Prostate Cancer (Clinical and Pathological N+, M+)

Definition, Epidemiology, Metastatic Spread, Diagnostic Evaluation, Hormone-Sensitive Disease, Castration Resistance, Systemic Therapy, Bone Health, and Prognosis

1. Definition and Clinical Overview

Metastatic prostate cancer refers to prostate malignancy that has spread beyond the primary prostate gland.

The historical source discusses both regional lymph node-positive prostate cancer and distant metastatic disease.

These categories must be distinguished because their prognosis and management differ.

Regional Lymph Node-Positive Disease

N1M0

Cancer has spread to regional pelvic lymph nodes without evidence of distant metastases.

It may be discovered:

  • On imaging before treatment.
  • During pathological examination of lymph nodes removed at radical prostatectomy.

Regional node-positive disease may remain amenable to treatment with long-term disease control or curative intent.

Distant Metastatic Disease

M1

Prostate cancer has spread beyond regional pelvic lymph nodes or to distant organs.

Important Metastatic Sites

  • Distant lymph nodes.
  • Bone.
  • Lung.
  • Liver.
  • Other organs.

Clinical Importance

Metastatic Prostate Cancer May Be Present At Initial Diagnosis Or Develop Following Previous Local Treatment, Including Radical Prostatectomy Or Radiotherapy.


2. TNM Classification

N1

Regional lymph node metastasis.

M1a

Nonregional lymph node metastasis.

M1b

Bone metastasis.

M1c

Visceral or other distant metastasis, with or without bone involvement.

Important Distinction

Pelvic Regional Nodal Disease (N1M0) Is Not Equivalent To Distant Metastatic Disease (M1).

Treatment recommendations must consider this distinction.


3. Hormone-Sensitive and Castration-Resistant Disease

Metastatic prostate cancer is also classified according to response to androgen suppression.

Metastatic Hormone-Sensitive Prostate Cancer

mHSPC, also called metastatic castration-sensitive prostate cancer (mCSPC).

Cancer remains responsive to androgen deprivation.

Metastatic Castration-Resistant Prostate Cancer

mCRPC.

Disease progresses despite testosterone being adequately suppressed to castrate levels.

Clinical Importance

Hormone Sensitivity Is A Major Determinant Of Systemic Treatment Selection.


4. Epidemiology

Historical Incidence

The source reports that approximately:

4% of patients presented with metastatic prostate cancer during 2003–2009

in the referenced United States SEER population.

Historical Mortality

Approximately:

28,800 deaths annually in the United States.

Important Qualification

These are historical figures.

They should not be treated as contemporary incidence or mortality estimates.

The frequency of metastatic presentation varies according to:

  • PSA screening.
  • Healthcare access.
  • Population characteristics.
  • Diagnostic methods.
  • Stage at presentation.


5. Risk Factors

The historical chapter identifies:

  • Family history of prostate cancer.
  • African American ancestry.
  • High-fat dietary patterns.

Contemporary Clinical Considerations

The risk of metastatic progression is more directly influenced by:

  • High ISUP Grade Group.
  • Advanced tumour stage.
  • High PSA.
  • Seminal vesicle invasion.
  • Lymph node involvement.
  • Aggressive cancer biology.
  • Inherited pathogenic variants.

Important Qualification

Historical population and dietary associations do not establish individual causation.


6. Genetic and Molecular Factors

Historical Source

The original chapter lists no specific genetic risk factors for metastatic prostate cancer.

Contemporary Understanding

Important molecular abnormalities include:

  • BRCA1.
  • BRCA2.
  • ATM.
  • Other homologous recombination repair genes.
  • Mismatch-repair deficiencies.
  • Microsatellite instability.

Clinical Importance

Genetic and molecular testing may influence:

  • Hereditary cancer counseling.
  • Treatment selection.
  • Eligibility for PARP inhibitor therapy.
  • Eligibility for immunotherapy in selected molecular subtypes.

Molecular Testing Is An Important Component Of Contemporary Metastatic Prostate Cancer Management.


7. Pathophysiology

Most prostate cancers arise from malignant transformation of prostatic glandular epithelial cells.

Principal Pathways of Spread

  1. Direct local invasion.
  2. Lymphatic spread.
  3. Hematogenous dissemination.

Lymphatic Spread

Cancer may initially involve:

  • Obturator lymph nodes.
  • Internal iliac lymph nodes.
  • External iliac lymph nodes.
  • Other pelvic nodal groups.

Further dissemination may involve nonregional lymph nodes.

Hematogenous Spread

Malignant cells may enter the systemic circulation and colonize distant tissues.


8. Batson Vertebral Venous Plexus

Definition

A network of valveless veins connecting pelvic venous structures with vertebral venous channels.

Proposed Role

Facilitates the spread of malignant cells from the pelvis to the vertebral column.

Clinical Importance

The Batson Venous Plexus Is An Important Anatomical Explanation For The Predilection Of Prostate Cancer To Metastasize To The Spine.


9. Bone Metastases

Bone is one of the most common sites of distant prostate cancer spread.

Common Locations

  • Vertebral column.
  • Pelvis.
  • Ribs.
  • Proximal femur.
  • Other axial skeletal structures.

Typical Radiological Pattern

Osteoblastic or sclerotic metastases.

Important Qualification

Mixed and predominantly lytic lesions may occur, particularly in some aggressive variants.

Clinical Consequences

  • Bone pain.
  • Pathological fractures.
  • Vertebral collapse.
  • Spinal cord compression.
  • Reduced mobility.
  • Impaired quality of life.


10. Androgen Biology

Prostate tissue growth is strongly influenced by androgens.

Important Hormones

  • Testosterone.
  • Dihydrotestosterone.

Historical Source

The chapter describes approximately:

  • 95% of circulating androgens as testicular in origin.
  • 5% as adrenal in origin.

Contemporary Qualification

This is a simplified description of androgen production.

In advanced disease, adrenal precursors and tumour-associated androgen synthesis may contribute to continued androgen receptor activation despite suppression of testicular testosterone.

Clinical Importance

Androgen Receptor Signaling Remains Central To Prostate Cancer Progression, Including In Many Cases Of Castration-Resistant Disease.


11. Clinical Presentation

Urinary Symptoms

Patients may present with:

  • Increased frequency.
  • Nocturia.
  • Hesitancy.
  • Weak urinary stream.
  • Difficulty maintaining urinary flow.
  • Dysuria.
  • Hematuria.
  • Urinary retention.

Important Qualification

These symptoms are nonspecific and may resemble benign prostatic hyperplasia.

Sexual Symptoms

  • Erectile dysfunction.
  • Other sexual dysfunction.

Systemic Symptoms

  • Fatigue.
  • Weight loss.
  • Reduced appetite.
  • General weakness.


12. Bone Pain

The historical source identifies bone pain as the most common symptom of metastatic disease.

Common Sites

  • Spine.
  • Pelvis.
  • Ribs.

Clinical Importance

New Persistent Skeletal Pain In A Patient With Prostate Cancer Raises Concern For Bone Metastases.


13. Neurological Symptoms

Metastatic involvement of the spine may cause:

  • Back pain.
  • Radicular pain.
  • Lower-limb weakness.
  • Sensory abnormalities.
  • Difficulty walking.
  • Urinary incontinence or retention.
  • Fecal incontinence.

Main Mechanisms

  • Vertebral instability.
  • Vertebral collapse.
  • Epidural tumour extension.
  • Compression of the spinal cord or cauda equina.


14. Metastatic Spinal Cord Compression

Definition

Compression of the spinal cord or cauda equina by metastatic tumour or associated vertebral pathology.

Important Warning Features

  • Severe progressive back pain.
  • New leg weakness.
  • Progressive sensory loss.
  • Difficulty walking.
  • New bladder dysfunction.
  • New bowel dysfunction.

Clinical Importance

Suspected Metastatic Spinal Cord Compression Is An Oncological Emergency.

Immediate Management Principles

  • Urgent neurological assessment.
  • Prompt MRI of the appropriate spinal region, usually the whole spine.
  • Immediate corticosteroid treatment when indicated.
  • Urgent spinal surgical and radiation oncology assessment.
  • Decompression, stabilization, and/or radiotherapy according to clinical circumstances.

The historical source emphasizes decompression within 24 hours of neurological symptom onset.

Contemporary Principle: Treatment Must Be Organized Urgently, But The Exact Procedure And Timing Depend On Neurological Status, Spinal Stability, Tumour Characteristics, And Patient Fitness.


15. Physical Examination

Digital Rectal Examination

May identify:

  • Nodular prostate.
  • Enlarged prostate.
  • Induration.
  • Local fixation.

After Radical Prostatectomy

The prostate bed may be:

  • Empty.
  • Associated with a palpable recurrence.

Lymph Node Examination

Assess for abnormal palpable lymphadenopathy.

Skeletal Examination

Evaluate:

  • Focal bone tenderness.
  • Vertebral tenderness.
  • Rib tenderness.
  • Gait abnormalities.

Neurological Examination

Assess:

  • Lower-limb strength.
  • Sensation.
  • Reflexes.
  • Gait.
  • Bladder and bowel function.


16. Laboratory Investigations

Serum PSA

An important marker for:

  • Baseline disease assessment.
  • Monitoring treatment response.
  • Detecting biochemical progression.

Clinical Importance

PSA Should Generally Be Measured Before Initiating Systemic Treatment And Monitored During Follow-Up.

Important Limitation

Some aggressive prostate cancer variants may progress with relatively low PSA.

Serum Testosterone

Used to confirm adequate androgen deprivation.

Historical Castration Threshold

Less than 50 ng/dL.

More Stringent Target

Testosterone below approximately:

20 ng/dL

may be desirable when achievable.

Additional Laboratory Tests

  • Complete blood count.
  • Serum creatinine.
  • Electrolytes.
  • Liver function.
  • Calcium.
  • Alkaline phosphatase.

These investigations support assessment of complications and treatment safety.


17. Prostatic Acid Phosphatase

The historical source reports elevated prostatic acid phosphatase in up to:

67% of patients with metastatic disease.

Important Qualification

This is a historical observation.

PSA and contemporary imaging are generally more central to modern prostate cancer assessment.


18. Diagnostic Imaging

Historical Investigations

The source recommends:

  • CT abdomen and pelvis.
  • Bone scintigraphy.

Main Objectives

  • Identify nodal metastases.
  • Detect bone metastases.
  • Evaluate local tumour extent.
  • Identify urinary obstruction.

Contemporary Imaging

PSMA PET/CT is an important tool for:

  • Initial staging in appropriate patients.
  • Detecting metastatic recurrence.
  • Defining disease distribution.
  • Selecting some PSMA-directed treatments.

Important Qualification

The evidence supporting treatment recommendations may use conventional CT and bone scan definitions of metastatic disease.

More sensitive PSMA PET can detect smaller lesions, so treatment decisions should account for differences in staging methods.


19. Evaluation of Hydronephrosis

Locally advanced or metastatic prostate cancer may cause ureteral obstruction.

Possible Mechanisms

  • Direct local tumour invasion.
  • Pelvic lymphadenopathy.
  • Distal ureteral compression.

Clinical Consequences

  • Hydroureteronephrosis.
  • Reduced kidney function.
  • Urinary infection.
  • Acute kidney injury.

Management Options

  • Ureteral stenting.
  • Percutaneous nephrostomy.
  • Appropriate treatment of the underlying malignancy.

Clinical Importance

Obstructive Renal Impairment Requires Prompt Assessment And May Need Urinary Drainage Before Or Alongside Systemic Cancer Treatment.


20. Histological Diagnosis

Main Histological Type

Prostatic adenocarcinoma.

Diagnostic Methods

  • Prostate biopsy.
  • Biopsy of a metastatic lesion when appropriate.

Clinical Importance

Histological confirmation is important when establishing a new diagnosis or evaluating an unusual clinical presentation.


21. Neuroendocrine Prostate Cancer

Important Clinical Features

  • Aggressive progression.
  • Relatively low PSA despite substantial disease burden.
  • Visceral metastases.
  • Lytic bone metastases.
  • Reduced dependence on androgen receptor signaling.

Historical Source

The chapter describes an association with very high Gleason scores.

Important Qualification

Pure small-cell neuroendocrine carcinoma is a distinct histological entity and is not routinely graded with the conventional Gleason system.

Clinical Importance

Rapid Clinical Progression With Low PSA, Visceral Metastases, Or Lytic Bone Lesions Should Raise Suspicion For Aggressive Variant Or Neuroendocrine Prostate Cancer.


22. Differential Diagnosis

Bone Lesions

Consider:

  • Prostate cancer metastases.
  • Paget disease.
  • Metastases from other cancers.
  • Other metabolic or neoplastic bone disorders.

Lymphadenopathy

Consider:

  • Metastatic prostate cancer.
  • Lymphoma.
  • Other malignancies.
  • Infectious or inflammatory causes.

Clinical Importance

Atypical lesions may require biopsy to confirm the diagnosis.


23. Clinical and Pathological Node-Positive Disease

cN1M0

Regional nodal involvement identified during pretreatment clinical staging.

pN1M0

Regional nodal metastases identified after radical prostatectomy and lymph node dissection.

These situations require different management considerations.


24. Treatment of cN1M0 Disease

Contemporary Treatment

Eligible patients are generally offered:

  • Definitive prostate and pelvic radiotherapy.
  • Long-term ADT.
  • Two years of abiraterone.

Clinical Importance

Regional Node-Positive, Nonmetastatic Prostate Cancer May Be Treated With Combined Local And Systemic Therapy With Long-Term Disease Control Or Curative Intent.


25. Treatment of pN1 After Radical Prostatectomy

The original chapter discusses trials of immediate versus delayed ADT.

Historical Findings

One randomized study suggested improved outcomes with immediate hormonal treatment in node-positive patients after surgery.

Other studies produced less consistent results.

Contemporary Management Options

After extended lymph node dissection:

  1. Adjuvant ADT.
  2. Adjuvant ADT with radiotherapy.
  3. Observation in carefully selected patients.

Observation May Be Appropriate When

  • Two or fewer regional lymph nodes are positive.
  • Postoperative PSA is undetectable.
  • Overall pathological risk is favorable.

Clinical Importance

Immediate Lifelong ADT Is Not Automatically Required In Every Patient With Limited pN1 Disease And An Undetectable Postoperative PSA.


26. Metastatic Hormone-Sensitive Prostate Cancer

mHSPC.

General Principle

The tumour remains responsive to suppression of androgen signaling.

Historical Source

The chapter describes ADT as the primary systemic treatment.

Contemporary Principle

Most Fit Patients With M1 Hormone-Sensitive Prostate Cancer Should Receive Treatment Intensification Beyond ADT Alone.

Main Treatment Categories

  • ADT plus androgen receptor pathway inhibitor.
  • ADT plus docetaxel and an androgen receptor pathway inhibitor in selected patients.
  • Additional prostate-directed radiation in selected patients with newly diagnosed low-volume metastatic disease.


27. Androgen-Deprivation Therapy

Main Objective

Reduce serum testosterone to castrate levels.

Treatment Methods

  • GnRH agonists.
  • GnRH antagonists.
  • Bilateral orchiectomy.

Important Historical Threshold

Testosterone below 50 ng/dL.

Clinical Importance

ADT remains the foundation of treatment for metastatic hormone-sensitive prostate cancer.


28. GnRH Agonists

Examples

  • Leuprolide.
  • Goserelin.
  • Triptorelin.

Mechanism

Continuous stimulation of pituitary GnRH receptors eventually suppresses LH release and testicular testosterone production.

Historical Onset

The source describes:

  • Initial testosterone rise approximately 7–10 days after treatment begins.
  • Medical castration after approximately 30 days.

Important Adverse Effect

Testosterone flare.


29. Testosterone Flare

Mechanism

GnRH agonists initially increase testosterone before inducing suppression.

Potential Consequences

  • Worsening bone pain.
  • Urinary obstruction.
  • Increased metastatic symptoms.
  • Spinal cord compression in susceptible patients.

Historical Prevention

Short-course first-generation antiandrogen treatment.

Contemporary Principle

Patients at risk of serious complications may be better treated initially with:

  • GnRH antagonist.
  • Orchiectomy.

Clinical Importance

Avoid Testosterone Flare In Patients With Impending Spinal Cord Compression Or Other Serious Obstructive Complications.


30. GnRH Antagonists

Historical Example

Degarelix.

Contemporary Additional Example

Relugolix.

Mechanism

Direct inhibition of pituitary GnRH receptors.

Main Advantages

  • Rapid testosterone reduction.
  • No initial testosterone flare.

Historical Degarelix Response

The source reports castrate testosterone concentrations in:

  • 44% by day 1.
  • 96% by day 3.

Important Qualification

These percentages reflect the original studied treatment regimen and should not be assumed to apply to every antagonist.


31. First-Generation Antiandrogens

Examples

  • Bicalutamide.
  • Flutamide.
  • Nilutamide.

Mechanism

Androgen receptor blockade.

Historical Uses

  • Prevention of GnRH agonist flare.
  • Combined androgen blockade.
  • Antiandrogen monotherapy.

Contemporary Qualification

First-generation antiandrogens are not equivalent to modern androgen receptor pathway inhibitors.

First-Generation Antiandrogen Monotherapy Is Not Recommended As Standard Treatment For M1 Prostate Cancer.


32. Intermittent Versus Continuous ADT

Historical Source

The chapter describes intermittent androgen deprivation as potentially providing similar survival in selected patients.

Proposed Benefits

  • Reduced treatment burden.
  • Improved sexual function during treatment breaks.
  • Lower cumulative toxicity.

Important Contemporary Qualification

Evidence in metastatic disease has not conclusively established equivalent survival for intermittent ADT across all risk groups.

Continuous androgen suppression remains the usual foundation of contemporary intensified metastatic treatment.

Clinical Importance

Intermittent ADT Should Not Automatically Be Assumed Equivalent To Continuous ADT In Patients Receiving Modern Metastatic Prostate Cancer Treatment.


33. Modern Androgen Receptor Pathway Inhibitors

Abiraterone

Inhibits CYP17-mediated androgen synthesis.

Administered with an appropriate corticosteroid regimen.

Enzalutamide

Inhibits androgen receptor signaling.

Apalutamide

A potent androgen receptor inhibitor.

Darolutamide

An androgen receptor inhibitor used in selected hormone-sensitive and castration-resistant settings.

Contemporary Guideline Context

Other agents, including rezvilutamide, appear in newer international guidance, with availability dependent on jurisdiction.

Clinical Importance

ADT Plus An Appropriate Modern Androgen Receptor Pathway Inhibitor Is A Standard Treatment Strategy For Most Eligible Patients With M1 Hormone-Sensitive Prostate Cancer.


34. Docetaxel in Metastatic Hormone-Sensitive Disease

Drug Class

Taxane chemotherapy.

Mechanism

Disrupts microtubule function and cell division.

Historical Trial

ECOG 3805 / CHAARTED.

Historical Finding

The source describes an approximately:

12-Month Overall Survival Advantage

with the addition of docetaxel to initial ADT in the historical study population.

Important Qualification

The magnitude of benefit varies according to disease burden and patient characteristics.


35. Contemporary Triplet Therapy

Definition

Combination of:

  1. ADT.
  2. Docetaxel.
  3. A modern androgen receptor pathway inhibitor.

Important Regimens

  • ADT + docetaxel + darolutamide.
  • ADT + docetaxel + abiraterone.

Clinical Role

Particularly relevant to fit patients with newly diagnosed, higher-volume metastatic disease.

Contemporary EAU Principle

For patients suitable for docetaxel, chemotherapy is generally incorporated into an appropriate triplet rather than routinely given as ADT–docetaxel doublet therapy.

Clinical Importance

Triplet Treatment Is An Important Option For Selected Fit Patients With Metastatic Hormone-Sensitive Prostate Cancer.


36. Metastatic Disease Volume

Clinical Importance

Metastatic burden influences prognosis and selection of additional local treatment.

CHAARTED High-Volume Definition

High-volume disease is defined as:

  • Visceral metastasis, or
  • At least four bone metastases, with at least one outside the vertebral column or pelvis.

Low-Volume Disease

Disease that does not meet the high-volume criteria.

Important Qualification

These classifications were developed using conventional imaging and should not be automatically reinterpreted using all additional lesions detected on PSMA PET.


37. Prostate Radiotherapy in Low-Volume Metastatic Disease

Clinical Context

Patients with newly diagnosed M1 disease and relatively limited metastatic burden may benefit from treatment of the primary prostate tumour.

Contemporary EAU Recommendation

Offer prostate radiotherapy with ADT-based systemic treatment to appropriate patients with:

De Novo Low-Volume M1 Disease.

Clinical Importance

Prostate Radiotherapy Can Improve Outcomes In Selected Patients With Newly Diagnosed Low-Volume Metastatic Hormone-Sensitive Prostate Cancer.

Important Qualification

This does not establish that radical prostatectomy routinely improves survival in M1 disease.

Surgery to the primary prostate tumour in metastatic disease generally remains a clinical-trial approach.


38. Metastasis-Directed Therapy

Definition

Treatment directed at individual metastatic lesions.

Possible Techniques

  • Stereotactic body radiotherapy.
  • Selected surgical procedures.

Potential Objectives

  • Delay progression.
  • Control individual lesions.
  • Reduce symptoms.

Contemporary Qualification

The survival benefit of routine metastasis-directed treatment in M1 prostate cancer remains incompletely established.

European guidance restricts routine use to clinical trials or well-designed prospective studies.


39. Castration-Resistant Prostate Cancer

CRPC.

Definition

Prostate cancer progression despite adequate androgen suppression.

Essential Testosterone Criterion

Less than 50 ng/dL.

Progression May Be

  • Biochemical.
  • Radiological.
  • Clinical, with corroborating evidence.

Important Clinical Principle

CRPC Requires Demonstration Of Disease Progression In The Presence Of Castrate Testosterone.

A rising PSA without confirmation of adequate testosterone suppression does not establish CRPC.


40. Metastatic Castration-Resistant Prostate Cancer

mCRPC.

Definition

Castration-resistant prostate cancer with metastatic disease.

Historical Source

The chapter describes progression after approximately:

1–4 Years of Initial ADT.

Important Qualification

The time to castration resistance varies considerably and has changed with modern combination treatment.

The historical figure should not be used as an individualized prediction.


41. Historical Secondary Hormonal Manipulation

The original source describes several approaches used after progression on primary ADT.

Antiandrogen Withdrawal

Stopping an existing antiandrogen may occasionally cause a PSA decline.

Historical Response

Approximately:

5–20%.

Addition of an Antiandrogen

Historical PSA response rates varied widely.

Ketoconazole

A historical inhibitor of androgen synthesis.

Important Qualification

These strategies largely predate contemporary androgen receptor inhibitors, molecularly targeted therapy, and radioligand treatment.

Ketoconazole And Sequential First-Generation Antiandrogen Manipulation Are No Longer Preferred Routine Treatment Strategies For mCRPC.


42. Contemporary Systemic Treatment of mCRPC

Treatment selection depends on:

  • Previous therapy.
  • Symptoms.
  • Performance status.
  • Metastatic burden.
  • Visceral metastases.
  • Molecular alterations.
  • Patient preferences.

Important Treatment Classes

  • Androgen receptor pathway inhibitors.
  • Taxane chemotherapy.
  • PARP inhibitors.
  • PSMA-directed radioligand treatment.
  • Bone-targeting radiopharmaceuticals.
  • Selected immunotherapies.

Clinical Importance

The Treatment Sequence for mCRPC Depends Strongly on Which Therapies Were Already Given During the Hormone-Sensitive Phase.


43. Androgen Receptor Pathway Inhibitors in mCRPC

Important Agents

  • Abiraterone with corticosteroid.
  • Enzalutamide.

Clinical Role

May provide disease control and survival benefit in appropriately selected patients.

Important Limitation

Sequential use of two androgen receptor pathway inhibitors may have limited benefit because of cross-resistance.

Other treatment classes should be considered when resistance develops.


44. Taxane Chemotherapy

Docetaxel

Used in metastatic hormone-sensitive or castration-resistant disease according to previous therapy.

Cabazitaxel

An important option after previous docetaxel and androgen receptor pathway treatment.

Important Adverse Effects

  • Neutropenia.
  • Febrile neutropenia.
  • Infection.
  • Fatigue.
  • Peripheral neuropathy.
  • Gastrointestinal toxicity.


45. PARP Inhibitors

Mechanism

Exploit defects in cancer cell DNA repair pathways.

Important Molecular Associations

  • BRCA1.
  • BRCA2.
  • Other homologous recombination repair alterations.

Important Treatments

  • Olaparib.
  • Selected PARP inhibitor combinations with androgen receptor pathway inhibitors.

Clinical Importance

Somatic And Germline Molecular Testing Can Identify Patients With mCRPC Who May Benefit From PARP Inhibitor-Based Treatment.

Important Qualification

The benefit and approved indications differ by the specific genetic alteration and treatment regimen.


46. PSMA-Directed Radioligand Therapy

Important Agent

Lutetium-177 PSMA-617.

Mechanism

A PSMA-binding ligand delivers therapeutic radiation to PSMA-expressing tumour cells.

Clinical Role

Selected PSMA-positive mCRPC.

Important Requirement

Appropriate PSMA PET imaging and treatment eligibility assessment.

Clinical Importance

PSMA-Directed Radioligand Therapy Is An Important Contemporary Treatment For Selected Patients With Advanced Metastatic Prostate Cancer.


47. Immunotherapy

Sipuleucel-T

An autologous cellular immunotherapy.

Historical Role

Selected asymptomatic or minimally symptomatic mCRPC.

Contemporary Qualification

Availability is geographically limited.

Pembrolizumab

May be considered in selected molecularly defined cancers, including some tumours with:

  • Microsatellite instability-high.
  • Mismatch-repair deficiency.

Clinical Importance

Immunotherapy is not routinely effective for all prostate cancers and generally requires appropriate patient selection.


48. Neuroendocrine Prostate Cancer Treatment

Main Principle

Aggressive neuroendocrine prostate cancer may be relatively resistant to conventional ADT-based treatment.

Historical Chemotherapy Regimens

  • Cisplatin + etoposide.
  • Carboplatin + etoposide.
  • Selected docetaxel-based regimens.

Contemporary Clinical Importance

Platinum-Based Chemotherapy Is An Important Treatment Option For Small-Cell Or Aggressive Neuroendocrine Prostate Cancer.

Treatment must reflect the actual histology and mixed tumour components.


49. Palliative Radiotherapy

Main Indication

Painful bone metastases.

Potential Benefits

  • Reduction of pain.
  • Improved local control.
  • Reduced symptom burden.

Other Indications

  • Threatened neurological complications.
  • Selected sites of local tumour progression.

Clinical Importance

External-Beam Radiotherapy Is Highly Effective For Palliation Of Painful Bone Metastases.


50. Surgical Management of Skeletal Metastases

Important Procedures

  • Spinal decompression.
  • Spinal stabilization.
  • Fixation of threatened weight-bearing bones.
  • Joint replacement in selected circumstances.

Main Objectives

  • Prevent pathological fracture.
  • Preserve neurological function.
  • Maintain mobility.
  • Reduce pain.

Clinical Importance

Patients with impending femoral or hip fracture may benefit from prophylactic orthopedic stabilization.


51. Historical Bone-Targeted Radiopharmaceuticals

The original chapter describes:

  • Strontium-89.
  • Samarium-153.

Mechanism

Beta-emitting radiopharmaceuticals used for palliation of bone pain.

Contemporary Context

These agents have largely been superseded by newer oncological treatments in many settings.


52. Radium-223

Mechanism

Bone-seeking alpha-emitting radiopharmaceutical.

Clinical Role

Selected patients with symptomatic bone-metastatic mCRPC and no visceral metastases.

Important Clinical Distinction

Radium-223 is not a general treatment for every form of metastatic prostate cancer.

Safety Considerations

  • Bone marrow suppression.
  • Fracture risk.
  • Appropriate bone protection.

Important Qualification

Certain combinations, particularly radium-223 with abiraterone-based therapy, have been associated with serious fracture-related safety concerns.


53. Bone Health During ADT

Long-term androgen suppression accelerates loss of bone mineral density.

Major Complications

  • Osteopenia.
  • Osteoporosis.
  • Fragility fractures.

Important Assessment

Obtain a baseline bone health evaluation when initiating long-term ADT.

Investigations

  • Bone mineral density measurement.
  • Fracture risk assessment.
  • Serum calcium and vitamin D when indicated.
  • Other metabolic bone investigations as appropriate.

Clinical Importance

Bone Health Assessment Is An Essential Part Of Long-Term ADT Management.


54. Calcium and Vitamin D

Historical Source Recommendation

  • Calcium: 1,200 mg/day.
  • Vitamin D: 800–1,000 IU/day.

Contemporary Interpretation

Ensure adequate total calcium and vitamin D intake, including dietary sources.

Supplementation should be individualized according to:

  • Nutritional intake.
  • Vitamin D status.
  • Kidney function.
  • Bone health.
  • Risk of hypercalcemia.

Clinical Importance

Adequate Calcium And Vitamin D Are Important, Particularly When Denosumab Or Bisphosphonates Are Prescribed.


55. Lifestyle Measures for Skeletal Health

Important Interventions

  • Weight-bearing exercise.
  • Resistance training.
  • Smoking cessation.
  • Adequate nutrition.
  • Falls prevention.
  • Appropriate activity modification when metastases threaten fracture.

Important Qualification

Exercise programs may need adjustment for skeletal instability or painful bone metastases.


56. Bone-Protective Medications

Main Classes

Bisphosphonates

  • Zoledronic acid.
  • Alendronate for selected osteoporosis indications.

RANK Ligand Inhibitors

  • Denosumab.

Clinical Importance

Bone-protective medications are used for two distinct purposes:

  1. Preventing osteoporosis-related fractures from ADT.
  2. Preventing skeletal-related events in mCRPC with bone metastases.

These Indications Require Different Doses And Treatment Strategies.


57. Denosumab Dosing

Osteoporosis-Related Indication

Historical source regimen:

60 mg subcutaneously every six months.

Prevention of Skeletal-Related Events in Appropriate mCRPC

Historical source regimen:

120 mg subcutaneously every four weeks.

Important Qualification

These regimens are not interchangeable.

Dose selection depends on the indication, regulatory approval, and the patient's clinical circumstances.


58. Zoledronic Acid

Historical mCRPC Regimen

4 mg intravenously approximately every 3–4 weeks.

Dose adjustment may be necessary according to renal function.

Osteoporosis Treatment

The dosing schedule differs from the oncology bone-metastasis regimen.

Important Qualification

The historical source's suggested annual 4 mg regimen should not be used as a universal osteoporosis prescription.

Clinical Importance

Renal Function Must Be Considered Before And During Zoledronic Acid Treatment.


59. Bone-Protective Therapy in mHSPC Versus mCRPC

mHSPC

Routine high-dose monthly denosumab or zoledronic acid solely to prevent metastatic skeletal-related events is not generally recommended.

Bone protection may still be necessary for osteoporosis or elevated fracture risk.

mCRPC With Bone Metastases

Denosumab or zoledronic acid may be used to reduce skeletal-related events.

Clinical Importance

The Indication for Bone-Protective Treatment Depends on Disease State and Bone Risk, Not Simply the Presence of Bone Metastases.


60. Skeletal-Related Events

Standard Clinical Events

  • Pathological fracture.
  • Spinal cord compression.
  • Radiation to bone.
  • Surgery to bone.

Important Qualification

The historical source also lists osteonecrosis of the jaw.

Osteonecrosis of the jaw is generally considered a complication of bone-modifying treatment rather than a conventional skeletal-related event caused by metastatic disease.


61. Osteonecrosis of the Jaw

Associated Treatments

  • Bisphosphonates.
  • Denosumab.

Important Risk Factors

  • Dental infection.
  • Tooth extraction.
  • Invasive dental procedures.
  • Poor oral health.
  • Prolonged antiresorptive exposure.

Prevention

  • Dental assessment before treatment.
  • Treatment of active dental disease.
  • Good oral hygiene.
  • Coordination of invasive dental care.

Clinical Importance

Dental Assessment Before High-Dose Bone-Modifying Therapy Helps Reduce The Risk Of Medication-Related Osteonecrosis Of The Jaw.


62. Hypocalcemia

Important Association

Particularly relevant during denosumab treatment.

Prevention

  • Assess baseline calcium.
  • Correct pre-existing hypocalcemia.
  • Ensure appropriate calcium and vitamin D intake.
  • Monitor calcium during therapy.

Important Consideration

Patients with significant kidney dysfunction may have a greater risk of severe hypocalcemia.


63. Prognosis

Historical Five-Year Survival

The original source reports:

28%.

Important Qualification

This is a historical estimate of survival in metastatic prostate cancer.

It is not an appropriate current individualized survival prediction.

Major Prognostic Factors

  • Hormone-sensitive versus castration-resistant disease.
  • Metastatic burden.
  • Presence of visceral metastases.
  • Performance status.
  • Gleason score or Grade Group.
  • PSA response.
  • Alkaline phosphatase.
  • Hemoglobin.
  • Molecular features.
  • Treatment received.


64. Historical Outcomes After ADT

Historical Median Time to Progression

18–24 Months.

Historical Median Survival After Progression on ADT

12–19 Months.

Important Qualification

These estimates reflect an older treatment era.

Modern combination therapy and subsequent life-prolonging treatments have substantially altered prognosis for many patients.


65. Historical Outcomes in Node-Positive Disease

The source describes a historical study suggesting that immediate ADT following radical prostatectomy in patients with positive regional lymph nodes increased overall survival.

Historical Reported Survival

  • Immediate ADT: 13.9 years.
  • Radical prostatectomy alone: 11.3 years.

Historical Mortality Reduction

Approximately:

46%.

Important Qualification

These results arose from a limited historical trial and do not establish the best treatment for every contemporary pN1 patient.

Current management incorporates nodal burden, postoperative PSA, radiation, and overall pathological risk.


66. Complications of ADT

Sexual Complications

  • Reduced libido.
  • Erectile dysfunction.
  • Loss of sexual function.

Vasomotor Effects

  • Hot flushes.

Body Composition Changes

  • Loss of skeletal muscle.
  • Increased body fat.
  • Weight gain.

Skeletal Effects

  • Osteopenia.
  • Osteoporosis.
  • Fractures.

Metabolic Effects

  • Insulin resistance.
  • Diabetes.
  • Dyslipidemia.

Other Effects

  • Fatigue.
  • Mood disturbance.
  • Possible cognitive effects.
  • Cardiovascular risk considerations.

Clinical Importance

ADT Requires Long-Term Monitoring Beyond PSA Because Treatment Can Affect Multiple Organ Systems.


67. Complications of Systemic Cancer Treatment

Androgen Receptor Pathway Inhibitors

Potential effects vary by medication and include:

  • Hypertension.
  • Fatigue.
  • Falls.
  • Drug interactions.
  • Hepatic abnormalities.
  • Electrolyte disturbances.

Chemotherapy

  • Neutropenia.
  • Febrile neutropenia.
  • Infection.
  • Peripheral neuropathy.
  • Fatigue.

PARP Inhibitors

  • Anemia.
  • Other cytopenias.
  • Fatigue.
  • Gastrointestinal toxicity.

Radioligand Therapy

  • Marrow suppression.
  • Fatigue.
  • Salivary gland symptoms.
  • Other treatment-specific adverse effects.


68. Follow-Up During Metastatic Treatment

PSA

The historical source recommends approximately:

Every Three Months After Starting ADT.

Testosterone

Assess periodically and particularly when PSA rises during hormonal treatment.

Other Monitoring

  • Full blood count.
  • Kidney function.
  • Liver function.
  • Calcium.
  • Metabolic health.
  • Bone health.
  • Symptoms.
  • Treatment toxicity.

Imaging

Repeat staging when:

  • Progression is suspected.
  • Symptoms change.
  • Treatment selection may be affected.

Important Clinical Principle

PSA Alone Does Not Fully Describe Disease Response, Especially in Aggressive Variant or Neuroendocrine Prostate Cancer.


69. Follow-Up of Castration-Resistant Disease

Important Assessments

  • PSA trend.
  • Serum testosterone.
  • New symptoms.
  • Radiological progression.
  • Performance status.
  • Previous treatment exposure.

Clinical Importance

Confirmation of adequate testosterone suppression is required before diagnosing castration resistance.

Additional Principle

ADT is generally continued during treatment of mCRPC.


70. Clinical and Surgical Pearls

Disease Classification

  • Regional N1M0 disease differs from distant M1 disease.
  • mHSPC and mCRPC represent distinct therapeutic states.
  • Bone and lymph nodes are common metastatic sites.
  • Bone metastases are usually osteoblastic.

Diagnostic Assessment

  • PSA is important for monitoring.
  • Testosterone confirms androgen suppression.
  • Imaging defines metastatic burden.
  • PSMA PET/CT is important in contemporary staging.
  • Atypical low-PSA progression may suggest neuroendocrine disease.

First-Line Systemic Treatment

  • ADT Is The Foundation Of Metastatic Hormone-Sensitive Treatment.
  • Most fit patients require treatment intensification.
  • Modern androgen receptor pathway inhibitors improve outcomes.
  • Triplet treatment is appropriate for selected patients.
  • Testosterone flare must be considered with GnRH agonists.

Regional Node-Positive Disease

  • cN1M0 disease may receive curative-intent combined treatment.
  • Selected pN1 patients with limited nodal disease and undetectable PSA may undergo observation.

Castration Resistance

  • Confirm testosterone below 50 ng/dL.
  • Evaluate biochemical and radiological progression.
  • Select further therapy according to prior treatment.
  • Molecular testing can identify targeted treatment opportunities.

Bone Health

  • Assess osteoporosis risk during ADT.
  • Prevent skeletal-related events.
  • Distinguish osteoporosis doses from metastatic bone disease doses.
  • Monitor calcium and kidney function.
  • Perform dental assessment before high-dose antiresorptive therapy.


71. Essential Examination Principles

1. Know the TNM Distinction

N1 is regional nodal disease; M1 indicates distant metastases.

2. Identify the Commonest Metastatic Sites

Bone and lymph nodes.

3. Remember the Typical Bone Pattern

Osteoblastic metastases.

4. Recognize the Most Important Symptom

Bone pain.

5. Identify Spinal Cord Compression Immediately

New neurological symptoms in a patient with spinal metastases require emergency assessment.

6. Know the Castrate Testosterone Threshold

Below 50 ng/dL.

7. Understand GnRH Agonist Flare

A temporary testosterone rise may worsen metastatic complications.

8. Know the Advantage of GnRH Antagonists

Rapid testosterone reduction without flare.

9. Do Not Routinely Use ADT Alone in Fit M1 Patients

Treatment intensification improves outcomes.

10. Know the Role of ARPIs

Abiraterone, enzalutamide, apalutamide, and darolutamide are important modern treatments.

11. Understand Triplet Treatment

ADT, docetaxel, and a suitable ARPI.

12. Remember Prostate Radiotherapy in Low-Volume M1 Disease

Selected newly diagnosed patients benefit from treatment of the primary tumour.

13. Distinguish mHSPC From mCRPC

Progression despite castrate testosterone defines castration resistance when appropriate progression criteria are met.

14. Continue ADT in mCRPC

Castrate testosterone should generally be maintained.

15. Consider Molecular Testing

DNA repair abnormalities may guide PARP inhibitor treatment.

16. Understand Radium-223

Used in selected symptomatic bone-metastatic mCRPC without visceral metastases.

17. Understand PSMA Radioligand Therapy

Lutetium-177 PSMA-617 is important for selected PSMA-positive mCRPC.

18. Protect Bone Health

ADT-induced osteoporosis and metastatic skeletal complications both require prevention and monitoring.

19. Distinguish Denosumab Doses

60 mg every six months for selected osteoporosis indications versus 120 mg every four weeks for appropriate oncology indications.

20. Monitor Treatment Toxicity

Renal, hepatic, metabolic, skeletal, hematological, and cardiovascular complications must be considered.


72. Historical Clinical Context and Important Qualifications

Historical Epidemiology

The original figures for metastatic presentation and prostate cancer mortality reflect an older United States population.

Historical Genetic Section

The source lists no genetic factors.

Modern care increasingly includes germline and somatic molecular testing.

ADT Monotherapy

The source describes ADT as first-line systemic treatment.

This remains foundational, but most fit patients with M1 hormone-sensitive disease benefit from treatment intensification.

Intermittent ADT

The historical chapter suggests similar outcomes with intermittent and continuous treatment in selected populations.

Contemporary intensified metastatic treatment generally maintains continuous androgen suppression.

Initial Docetaxel Treatment

The historical chapter describes the survival advantage from adding docetaxel to ADT.

Current practice often favors ADT plus an ARPI, with docetaxel incorporated into selected triplet regimens.

Antiandrogen Withdrawal and Ketoconazole

These were historically used for progression after primary hormone suppression.

Modern treatment options generally provide more substantial clinical benefit.

Castration Resistance

The original chapter emphasizes PSA elevation during castrate testosterone.

Contemporary assessment also recognizes radiological progression and the need for adequate progression criteria.

Regional Nodal Disease

Historical discussion of early versus delayed ADT should not be directly applied to every cN1M0 or pN1M0 patient.

Skeletal-Related Events

Osteonecrosis of the jaw is better considered a bone-modifying treatment complication than a conventional skeletal-related event.

Bone-Modifying Drugs

The indication and dose differ for osteoporosis, mHSPC, and mCRPC with bone metastases.

Historical Survival

The figures of 28% five-year survival, 18–24 months to progression, and 12–19 months after ADT progression are historical and should not be used as current personalized predictions.


73. Historical Diagnostic Codes

ICD-9

185

Malignant neoplasm of prostate.

196.5

Secondary and unspecified malignant neoplasm of lymph nodes of the inguinal region and lower limb.

198.5

Secondary malignant neoplasm of bone and bone marrow.

ICD-10 Codes Listed in the Source

C61

Malignant neoplasm of prostate.

C77.4

Secondary and unspecified malignant neoplasm of inguinal and lower-limb lymph nodes.

C79.51

Secondary malignant neoplasm of bone.

Important Coding Qualification

The historical source's inguinal lymph node code should not be assumed to represent all regional pelvic prostate cancer lymph node metastases.

Coding must distinguish regional nodal involvement, nonregional metastases, and bone metastases according to the documented anatomy and applicable classification.


Final Urological Revision Summary

Metastatic prostate cancer involves regional nodal disease or distant spread from the primary prostate tumour, with the most common distant sites being bone and nonregional lymph nodes.

Major Clinical Categories

cN1M0 or pN1M0

Regional lymph node-positive disease without distant metastases.

mHSPC

Distant metastatic disease that remains responsive to androgen deprivation.

mCRPC

Metastatic cancer progressing despite castrate testosterone.

Principal Clinical Features

  • Bone pain.
  • Urinary symptoms.
  • Pelvic discomfort.
  • Hematuria.
  • Weight loss.
  • Skeletal complications.
  • Neurological symptoms from spinal metastases.

Main Diagnostic Priorities

  1. Confirm histological diagnosis when needed.
  2. Measure PSA.
  3. Assess testosterone.
  4. Establish metastatic distribution.
  5. Evaluate bone involvement.
  6. Assess renal obstruction.
  7. Consider PSMA PET/CT when appropriate.
  8. Evaluate genetic and molecular alterations.
  9. Identify neurological emergencies.

Main Contemporary Treatments

Regional N1M0 Disease

  • Definitive radiotherapy with long-term hormonal treatment for eligible cN1 patients.
  • Individualized adjuvant treatment or observation after surgery for pN1 disease.

Metastatic Hormone-Sensitive Disease

  • ADT plus a modern androgen receptor pathway inhibitor.
  • Selected triplet therapy with docetaxel.
  • Prostate radiotherapy in appropriate de novo low-volume disease.

Metastatic Castration-Resistant Disease

  • Continued ADT.
  • ARPIs according to previous exposure.
  • Docetaxel.
  • Cabazitaxel.
  • PARP inhibitors for eligible molecular subtypes.
  • Lutetium-177 PSMA radioligand therapy.
  • Radium-223 in selected bone-metastatic disease.
  • Selected immunotherapy.

Important Supportive Treatments

  • Palliative radiotherapy.
  • Management of spinal cord compression.
  • Orthopedic stabilization when appropriate.
  • Prevention of osteoporosis.
  • Bone-modifying agents for appropriate indications.
  • Pain management.
  • Management of urinary obstruction.
  • Nutritional and functional support.

Main Complications

  • Pathological fracture.
  • Spinal cord compression.
  • Hydronephrosis.
  • Renal impairment.
  • Pain and disability.
  • ADT-induced osteoporosis.
  • Metabolic complications.
  • Cardiovascular risk.
  • Chemotherapy-related toxicity.
  • Osteonecrosis of the jaw.
  • Hypocalcemia.

Follow-Up Priorities

  • PSA response.
  • Serum testosterone.
  • Imaging for suspected progression.
  • Bone health.
  • Kidney function.
  • Blood counts.
  • Metabolic health.
  • Treatment-related toxicity.
  • Quality of life.

The Central Urological Objective Is To Distinguish Regional Node-Positive Disease From Distant Metastases, Identify Hormone Sensitivity, Provide Effective Combination Systemic Treatment, Prevent Skeletal And Neurological Complications, Use Molecularly Targeted Therapies When Appropriate, And Maintain Long-Term Symptom Control And Quality Of Life.

 

Image description
0 Comments